Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

INTRODUCTION: Bone marrow (BM) is an immunologically privileged site where activated autoantibody-producing B cells may survive for prolonged periods. We investigated the effect of rituximab (anti-CD20 mAb) in peripheral blood (PB) and BM B-cell and T-cell populations in active rheumatoid arthritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakou, Magda, Katsikas, Georgios, Sidiropoulos, Prodromos, Bertsias, George, Papadimitraki, Eva, Raptopoulou, Amalia, Koutala, Helen, Papadaki, Helen A, Kritikos, Herakles, Boumpas, Dimitrios T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745815/
https://www.ncbi.nlm.nih.gov/pubmed/19715572
http://dx.doi.org/10.1186/ar2798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745815/
https://www.ncbi.nlm.nih.gov/pubmed/19715572
http://dx.doi.org/10.1186/ar2798

Ejemplares similares